PCRX Logo

Pacira BioSciences, Inc. (PCRX) 

NASDAQ$22.87
Market Cap
$1.06B
Sector
Healthcare
Industry
Drug Manufacturers—Specialty & Generic
Rank in Sector
235 of 924
Rank in Industry
10 of 56

PCRX Insider Trading Activity

PCRX Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$215,684638
Sells
$653,6011062

Related Transactions

Lee Frank D.Chief Executive Officer1$99,9940$0$99,994
BIGAL MARCELOdirector2$60,8680$0$60,868
YANG MICHAEL J.director1$25,8000$0$25,800
Froimson Markdirector1$16,2120$0$16,212
Brege Lauradirector1$12,8100$0$12,810
HASTINGS PAUL Jdirector0$01$24,974$-24,974
GAUGLER DARYLChief Operating Officer0$03$44,690$-44,690
RIKER LAURENSenior Vice President, Finance0$01$114,018$-114,018
WILLIAMS KRISTENChief Administrative Officer0$01$211,488$-211,488
SLONIN JONATHANChief Medical Officer0$04$258,431$-258,431

About Pacira BioSciences, Inc.

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that â€¦

Insider Activity of Pacira BioSciences, Inc.

Over the last 12 months, insiders at Pacira BioSciences, Inc. have bought $215,684 and sold $653,601 worth of Pacira BioSciences, Inc. stock.

On average, over the past 5 years, insiders at Pacira BioSciences, Inc. have bought $215,684 and sold $17.1M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Lee Frank D. (Chief Executive Officer) — $99,994. BIGAL MARCELO (director) — $60,868. YANG MICHAEL J. (director) — $25,800.

The last purchase of 1,512 shares for transaction amount of $20,034 was made by BIGAL MARCELO (director) on 2024‑08‑16.

List of Insider Buy and Sell Transactions, Pacira BioSciences, Inc.

2025-01-06SaleSLONIN JONATHANChief Medical Officer
879
0.0019%
$18.40$16,174+33.25%
2024-12-13SaleGAUGLER DARYLChief Operating Officer
500
0.0011%
$19.76$9,880+17.04%
2024-09-13SaleGAUGLER DARYLChief Operating Officer
500
0.0011%
$12.86$6,430+43.10%
2024-08-16PurchaseBrege Lauradirector
1,000
0.0023%
$12.81$12,810+36.24%
2024-08-16PurchaseBIGAL MARCELOdirector
1,512
0.0036%
$13.25$20,034+36.24%
2024-08-14PurchaseYANG MICHAEL J.director
2,000
0.0046%
$12.90$25,800+40.74%
2024-08-12PurchaseLee Frank D.Chief Executive Officer
8,264
0.0178%
$12.10$99,994+42.39%
2024-08-12PurchaseFroimson Markdirector
1,400
0.0029%
$11.58$16,212+42.39%
2024-08-12PurchaseBIGAL MARCELOdirector
3,400
0.0073%
$12.01$40,834+42.39%
2024-08-02SaleSLONIN JONATHANChief Medical Officer
945
0.0019%
$20.05$18,947-17.45%
2024-07-02SaleSLONIN JONATHANChief Medical Officer
2,836
0.0062%
$28.25$80,117-17.15%
2024-06-13SaleGAUGLER DARYLChief Operating Officer
1,000
0.0021%
$28.38$28,380-32.32%
2024-06-13SaleWILLIAMS KRISTENChief Administrative Officer
7,452
0.0157%
$28.38$211,488-32.32%
2024-06-13SaleHASTINGS PAUL Jdirector
880
0.0019%
$28.38$24,974-32.32%
2024-06-12SaleRIKER LAURENSenior Vice President, Finance
3,970
0.0085%
$28.72$114,018-32.93%
2024-06-11SaleSLONIN JONATHANChief Medical Officer
5,012
0.0106%
$28.57$143,193-33.48%
2024-03-08SalePACE GARY Wdirector
90,000
0.1889%
$30.60$2.75M-32.73%
2024-03-07SalePACE GARY Wdirector
28,257
0.0613%
$30.81$870,598-30.83%
2024-03-06SalePACE GARY Wdirector
1,066
0.0023%
$29.67$31,628-29.61%
2023-08-02SaleWINSTON ROYChief Medical Officer
509
0.0011%
$34.88$17,751-19.83%
Total: 430
*Gray background shows transactions not older than one year

Insider Historical Profitability

22.98%
Lee Frank D.Chief Executive Officer
107784
0.2329%
$2.47M10
Brege Lauradirector
17552
0.0379%
$401,414.2416
Froimson Markdirector
14473
0.0313%
$330,997.5122<0.0001%
HASTINGS PAUL Jdirector
12724
0.0275%
$290,997.88118+79.52%
BIGAL MARCELOdirector
10142
0.0219%
$231,947.5420
*Gray background shows insiders who have made transactions during last year

Historical Insider Profitability vs. Competitors

$910,099,463
123
11.52%
$2.63B
$187,390,806
89
12.63%
$777.44M
$12,681,496
70
20.90%
$804.92M
$14,599,168
59
12.79%
$1.36B
$23,522,750
59
-6.74%
$5.16B

PCRX Institutional Investors: Active Positions

Increased Positions114+39.86%8M+15.58%
Decreased Positions122-42.66%10M-18.54%
New Positions37New3MNew
Sold Out Positions44Sold Out2MSold Out
Total Postitions278-2.8%50M-2.96%

PCRX Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Blackrock, Inc.$185,421.0016.76%7.71M-77,580-1%2024-12-31
Vanguard Group Inc$126,597.0011.44%5.26M-34,764-0.66%2024-12-31
Pacer Advisors, Inc.$78,471.007.09%3.26M-2M-34.25%2024-12-31
D. E. Shaw & Co., Inc.$54,292.004.91%2.26M+300,536+15.36%2024-12-31
Renaissance Technologies Llc$47,922.004.33%1.99M+13,604+0.69%2024-12-31
State Street Corp$47,270.004.27%1.97M-48,544-2.41%2024-12-31
Dimensional Fund Advisors Lp$44,065.003.98%1.83M-40,154-2.15%2024-12-31
Doma Perpetual Capital Management Llc$42,036.003.8%1.75M00%2024-12-31
Millennium Management Llc$35,727.003.23%1.49M+879,473+145.12%2024-12-31
Ubs Group Ag$33,064.002.99%1.37M+1M+620.71%2024-12-31

Financial Ratios

Summary
Comparison with Competitors

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.